Beth Seidenberg

Beth joined Kleiner Perkins Caufield & Byers in May 2005, to work in the life sciences area. She has been involved with helping their portfolio companies and launching the Pandemic Preparedness & Biodefense fund. She is currently on the Board of Directors of three companies, most recently joining BioCryst. Her primary focus is in novel therapeutics to treat unmet medical needs.

Beth was formerly the Senior Vice President, Global Development, and Chief Medical Officer at Amgen, Inc., the world’s largest biotechnical company. Prior to joining Amgen, Beth was a senior executive in research and development at Bristol-Myers Squibb Company and Merck & Co., Inc. She began her career in basic and clinical research at the National Institutes of Health specializing in immunology and infectious diseases. In total, she introduced 10 innovative products to market and achieved over 40 regulatory approvals (including new indications and formulations) on a worldwide basis. These products have been successfully commercialized and have provided benefits to millions of patients with grievous illnesses and generated several billion dollars of revenue.

Beth received her B.S. from Barnard College magna cum laude, Phi Beta Kappa; and her medical degree from the University Of Miami School Of Medicine, alpha omega alpha. Her post-graduate training was completed at Johns Hopkins, George Washington School of Medicine and the National Institutes of Health. She is a trustee of Barnard College and a member of the Science Advisory Board.